GSK - Summary financial statements banner image
  • Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers
GlaxoSmithKline logo

Summary information under US GAAPSummary remuneration report


The following is a summary of the material adjustments to profit and shareholders' funds which would be required if US Generally Accepted Accounting Principles (US GAAP) had been applied instead of IFRS.

Summary information under US GAAP

PROFIT

2005
£m
2004
£m
Profit after taxation for the year under IFRS 4,816 4,022
Profit attributable to minority interests (127) (114)
Profit attributable to shareholders under IFRS 4,689 3,908
US GAAP adjustments:    
- Product rights (1,682) (1,651)
- Capitalised interest (1) (17)
- Disposal of interests in associates and subsidiaries - (97)
- Equity investments (2) (30)
- Employee costs (121) (113)
- Derivative instruments and hedging (30) 50
- Restructuring 1 (12)
- Taxation 538 747
- Other (56) (53)
Net income under US GAAP    3,336 2,732
Basic income per share under US GAAP 58.8p 47.6p
Diluted income per share under US GAAP 58.3p 47.5p
     

EQUITY SHAREHOLDERS' FUNDS

2005
£m
2004
£m
Total equity under IFRS 7,570 5,937
Minority interests (259) (213)
Shareholders’ equity under IFRS 7,311 5,724

US GAAP adjustments:

   
- Product rights and goodwill       30,041 31,573
- Fixed assets      212 223
- Marketable securities - 49
- Other investments 576 532
- Employee costs 1,249 1,230
- Restructuring 65 80
- Derivative instruments and hedging (33) 2
- Dividends (568) (571)
- Deferred taxation (4,531) (4,840)
- Other (40) 40
Shareholders’ equity under US GAAP 34,282 34,042

A summary of the material differences between IFRS and US GAAP that apply to the Group is set out in the Annual Report 2005.